[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know",
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $825.91, indicating a +0.41% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=51c11e32ee55710e9e29881813cbb5fa19f626fed2b8d9b7770bbcdb480bc7da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743457515,
      "headline": "Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know",
      "id": 133632947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $825.91, indicating a +0.41% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=51c11e32ee55710e9e29881813cbb5fa19f626fed2b8d9b7770bbcdb480bc7da"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Unveils Positive Phase 2 Results For Heart Disease Therapy Amid 5% Share Dip",
    "summary": "Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments. The company reported strong financial results, with significant year-over-year earnings growth. Further bolstering its stock was the announcement of successful Phase 2 results for lepodisiran, which reduced lipoprotein(a) levels, a genetic heart disease risk factor. Additionally, the company's expansion in digital healthcare and strategic partnerships, like those with...",
    "url": "https://finnhub.io/api/news?id=96fe43f7185e471142f3db2093a873bcdc04583e90cc5d71687f88fdee8dd74b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743442140,
      "headline": "Eli Lilly (NYSE:LLY) Unveils Positive Phase 2 Results For Heart Disease Therapy Amid 5% Share Dip",
      "id": 133632948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments. The company reported strong financial results, with significant year-over-year earnings growth. Further bolstering its stock was the announcement of successful Phase 2 results for lepodisiran, which reduced lipoprotein(a) levels, a genetic heart disease risk factor. Additionally, the company's expansion in digital healthcare and strategic partnerships, like those with...",
      "url": "https://finnhub.io/api/news?id=96fe43f7185e471142f3db2093a873bcdc04583e90cc5d71687f88fdee8dd74b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%",
    "summary": "Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint. Participants who recei",
    "url": "https://finnhub.io/api/news?id=4c740a938097d3f3cf5c3d4092faa9fe350ef7ae619a7828a8e2d38d8d80e2ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743439155,
      "headline": "Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%",
      "id": 133627773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint. Participants who recei",
      "url": "https://finnhub.io/api/news?id=4c740a938097d3f3cf5c3d4092faa9fe350ef7ae619a7828a8e2d38d8d80e2ca"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Q1 2025 Recap: Winners And Underperformers",
    "summary": "Biotech Stocks Q1 2025 Recap: Winners And Underperformers",
    "url": "https://finnhub.io/api/news?id=fca2009a34592e24b4f3882a92027b0a12ab50ad4e5643e6b09744fc6b98a472",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743431649,
      "headline": "Biotech Stocks Q1 2025 Recap: Winners And Underperformers",
      "id": 133628853,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=fca2009a34592e24b4f3882a92027b0a12ab50ad4e5643e6b09744fc6b98a472"
    }
  },
  {
    "ts": null,
    "headline": "Is the Future Bleak for SAVA Stock Following Another Setback?",
    "summary": "The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.",
    "url": "https://finnhub.io/api/news?id=7d84c3daf4c126a4152f12fd1ffd0164e0ab8c50603f755bccb5b231201ede9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743429600,
      "headline": "Is the Future Bleak for SAVA Stock Following Another Setback?",
      "id": 133627774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.",
      "url": "https://finnhub.io/api/news?id=7d84c3daf4c126a4152f12fd1ffd0164e0ab8c50603f755bccb5b231201ede9e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trial",
    "summary": "The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.",
    "url": "https://finnhub.io/api/news?id=cc1aecd576ccce6659325effc82ea05199bb2649bfc8534678daca5cced4ee9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743421977,
      "headline": "Eli Lilly’s lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trial",
      "id": 133625655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.",
      "url": "https://finnhub.io/api/news?id=cc1aecd576ccce6659325effc82ea05199bb2649bfc8534678daca5cced4ee9c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels",
    "summary": "INDIANAPOLIS - Eli Lilly and Company today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA therapy designed to lower the production of lipoprotein [Lp],...",
    "url": "https://finnhub.io/api/news?id=9a76a18bc8076fc11b5274aeb0eb1ecbd1c4a78f585aa7086e59ab07f0007058",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743421942,
      "headline": "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels",
      "id": 133626949,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA therapy designed to lower the production of lipoprotein [Lp],...",
      "url": "https://finnhub.io/api/news?id=9a76a18bc8076fc11b5274aeb0eb1ecbd1c4a78f585aa7086e59ab07f0007058"
    }
  },
  {
    "ts": null,
    "headline": "PGIM Jennison Global Opportunities Fund Q4 2024 Commentary",
    "summary": "The PGIM Jennison Global Opportunities Fund returned -0.6%, holding up slightly better than the MSCI ACWI Index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=4e3ccc7be59fb7d5a1ce2d2968438f82e1cc05399ebdc5fbccad36a50cfe99f3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743419700,
      "headline": "PGIM Jennison Global Opportunities Fund Q4 2024 Commentary",
      "id": 133626837,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206067205/image_2206067205.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The PGIM Jennison Global Opportunities Fund returned -0.6%, holding up slightly better than the MSCI ACWI Index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=4e3ccc7be59fb7d5a1ce2d2968438f82e1cc05399ebdc5fbccad36a50cfe99f3"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Large Cap Growth ETF Q4 2024 Commentary",
    "summary": "The Hartford Large Cap Growth ETF outperformed the Russell 1000 Growth Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=bf78413d48a567a0da9ddb002836cce45043b5ae2b518a354a64f1e316b804b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743415320,
      "headline": "Hartford Large Cap Growth ETF Q4 2024 Commentary",
      "id": 133626511,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1009092686/image_1009092686.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Hartford Large Cap Growth ETF outperformed the Russell 1000 Growth Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=bf78413d48a567a0da9ddb002836cce45043b5ae2b518a354a64f1e316b804b7"
    }
  },
  {
    "ts": null,
    "headline": "In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly",
    "summary": "The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.",
    "url": "https://finnhub.io/api/news?id=3a534c993744a33991869ecb461440bc7086bcd4bbcca27c5daa6e8c049f08e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743405799,
      "headline": "In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly",
      "id": 133625656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.",
      "url": "https://finnhub.io/api/news?id=3a534c993744a33991869ecb461440bc7086bcd4bbcca27c5daa6e8c049f08e9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Phase 2 Lipoprotein(a) Study Hits Primary Endpoint",
    "summary": "By Colin Kellaher Eli Lilly said an experimental drug nearly eliminated an inherited type of bad cholesterol at its highest dose in a mid-stage study. Eli Lilly on Sunday said the Phase 2...",
    "url": "https://finnhub.io/api/news?id=538f9e33a3381e9835765c9f096678ff238f78324cadca002702efc9c50ae928",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743405131,
      "headline": "Eli Lilly Phase 2 Lipoprotein(a) Study Hits Primary Endpoint",
      "id": 133625004,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Eli Lilly said an experimental drug nearly eliminated an inherited type of bad cholesterol at its highest dose in a mid-stage study. Eli Lilly on Sunday said the Phase 2...",
      "url": "https://finnhub.io/api/news?id=538f9e33a3381e9835765c9f096678ff238f78324cadca002702efc9c50ae928"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Chinese Tech Stops Slip",
    "summary": "Wall Street Breakfast Podcast: Chinese Tech Stops Slip",
    "url": "https://finnhub.io/api/news?id=f302c065261f08610f268f1a34a701af31fdc678db17f85fca9fd4da0713fd9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743404569,
      "headline": "Wall Street Breakfast Podcast: Chinese Tech Stops Slip",
      "id": 133625020,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f302c065261f08610f268f1a34a701af31fdc678db17f85fca9fd4da0713fd9d"
    }
  },
  {
    "ts": null,
    "headline": "PGIM Jennison Growth Fund Q4 2024 Commentary",
    "summary": "The PGIM Jennison Growth Fund rose 6.5%, slightly underperforming the Russell 1000 Growth Index for Q4 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=3f80a2cc5e443d35bd30910a4935fca083b85186e73e3e8f91cfaf0905c9ea6f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743404100,
      "headline": "PGIM Jennison Growth Fund Q4 2024 Commentary",
      "id": 133624949,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197707031/image_2197707031.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The PGIM Jennison Growth Fund rose 6.5%, slightly underperforming the Russell 1000 Growth Index for Q4 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=3f80a2cc5e443d35bd30910a4935fca083b85186e73e3e8f91cfaf0905c9ea6f"
    }
  },
  {
    "ts": null,
    "headline": "PGIM Jennison Focused Growth Fund Q4 2024 Commentary",
    "summary": "PGIM Jennison Focused Growth Fund Q4 2024 Commentary",
    "url": "https://finnhub.io/api/news?id=737ff5ee66dd78153317776bacd4fec7f6e999436982756dea21c4a22bae1c46",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743403200,
      "headline": "PGIM Jennison Focused Growth Fund Q4 2024 Commentary",
      "id": 133624801,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=737ff5ee66dd78153317776bacd4fec7f6e999436982756dea21c4a22bae1c46"
    }
  },
  {
    "ts": null,
    "headline": "John Hancock U.S. Growth Fund Q4 2024 Commentary",
    "summary": "For Q4 2024, the John Hancock U.S. Growth Fund underperformed the benchmark Russell 1000 Growth Index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=bc200f8c1a9602b78c94fb644680e14dd05970f20a5f2aab6b5d98a5210183bb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743396300,
      "headline": "John Hancock U.S. Growth Fund Q4 2024 Commentary",
      "id": 133624187,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152594082/image_2152594082.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q4 2024, the John Hancock U.S. Growth Fund underperformed the benchmark Russell 1000 Growth Index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=bc200f8c1a9602b78c94fb644680e14dd05970f20a5f2aab6b5d98a5210183bb"
    }
  }
]